Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 ...

Precision intelligence offers a path forward – pharma-specific, human-led and already in use by teams managing complex, ...

Identifying the right specialists with precision data In rare disease, access to treatment starts long before launch. Patient populations are small and dispersed, and the physicians who treat them ...

Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments ...

These rules apply to pharma. For distribution, medicine approvals and access are essential. For mental availability, brands ...

In a deal worth $950m, GSK has agreed to acquire 35Pharma, a private, clinical-stage biopharmaceutical company based in Canada that specialises in the development of novel protein-based therapeutics.

Ethan Mollick’s idea of the ‘jagged frontier’ of AI 1 is one of the most useful ways of describing the problem with the ...

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when ...

As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) ...

The race to harness and exploit generative AI (GenAI) in healthcare is at a feverish state, with agencies and pharmaceutical companies building platforms and creative departments plundering ...

Incyte Biosciences UK has received NICE approval for eligible NHS patients with non-segmental vitiligo to be reimbursed for Opzelura (ruxolitinib) cream 15mg/g. This comes after more than two years of ...

This month we have a special feature on GenAI and its impact on pharma – from intelligent content generation to optimising ...